[Intensification of a diffuse chronic pain syndrome by the introduction of an aromatase inhibitor].

Abstract

A case of a menopausal woman known for a chronic diffuse pain syndrome and breast cancer positive for estrogen receptors is presented. She developed an increase of her diffuse pain syndrome and joint aches after the introduction of an aromatase inhibitor. Soreness quickly improved after the interruption of the drug. We emphasize some etiological hypotheses concerning the painful symptoms, especially the role of aromatase and estrogens.

• Authors: N Nemitz, P T Kurmann, D Van Linthoudt
• Journal: Praxis (Praxis (Bern 1994)) Vol. 97 Issue 3 Pg. 137-41 (Feb 06 2008) ISSN: 1661-8157 [Print] Switzerland
• Vernacular Title: Exacerbation d'un syndrome douloureux chronique diffus par l'introduction d'un inhibi- teur de l'aromatase.
• PMID: 18549014 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antineoplastic Agents, Hormonal
• Aromatase Inhibitors
• Nitriles
• Receptors, Estrogen
• Receptors, Progesterone
• Triazoles
• Anastrozole

Topics

• Aged
• Anastrozole
• Antineoplastic Agents, Hormonal (adverse effects, therapeutic use)
• Aromatase Inhibitors (adverse effects, therapeutic use)
• Breast Neoplasms (drug therapy, pathology, surgery)
• Carcinoma, Ductal (drug therapy, pathology, surgery)
• Chemotherapy, Adjuvant
• Combined Modality Therapy
• Disease Progression
• Female
• Fibromyalgia (chemically induced, diagnosis)
• Humans
• Mastectomy
• Neoplasms, Hormone-Dependent (drug therapy, pathology, surgery)
• Nitriles (adverse effects, therapeutic use)
• Receptors, Estrogen (analysis, drug effects)
• Receptors, Progesterone (analysis, drug effects)
• Triazoles (adverse effects, therapeutic use)